BCR-ABL1 is the fusion protein born from the Philadelphia chromosome, the hallmark genetic abnormality of chronic myeloid leukemia and a subset of B-cell acute lymphoblastic leukemia. First described in landmark reviews by Goldman and Melo, the fusion fuses the BCR gene on chromosome 22 with the ABL1 tyrosine kinase gene on chromosome 9, producing a constitutively active kinase that drives uncontrolled proliferation and survival of white blood cells. Tyrosine kinase inhibitors were designed to slip into the ATP-binding pocket of ABL1 and freeze the enzyme in an inactive state. In structural studies of the kinase domain, including work by Cowan-Jacob and colleagues, imatinib and related compounds achieve exactly that. And yet, in patients, the kinetics of treatment response are markedly slower than direct enzyme inhibition would predict, an effect sometimes described as target sluggishness.

The new research reframes this sluggishness as an emergent property of how BCR-ABL1 organizes itself inside the cell. Rather than floating freely through the cytoplasm as isolated molecules, the team found that BCR-ABL1 molecules condense into dense, membraneless assemblies reminiscent of liquid droplets. These condensates form through multivalent, weak interactions among intrinsically disordered regions of the protein, the same class of physical chemistry that governs the formation of cellular structures such as nucleoli, stress granules and P bodies. The study connects this condensate behavior directly to therapeutic response: when BCR-ABL1 resides within these droplets, the local molecular environment becomes a physical barricade that slows the entry and action of tyrosine kinase inhibitors.

The concept of phase separation has transformed cell biology over the past decade. In a widely cited 2018 paper in Cell, Qamar and colleagues demonstrated that low-complexity protein domains can undergo liquid-liquid phase separation, creating compartments whose material properties dictate how molecules exchange with the surrounding cytoplasm. The new study applies this framework to cancer signaling for the first time in the context of targeted therapy. The authors showed that disrupting the conditions that promote condensate formation made BCR-ABL1 more accessible to drugs, while conditions that stabilized the droplets exaggerated the sluggish response. The droplet, in effect, functions as a microscopic shelter: drug molecules can reach the droplet surface, but penetrating the dense interior to reach every kinase molecule takes far longer than engaging freely diffusing protein.

Technically, the researchers combined protein biochemistry with cellular assays and clinical material. They purified BCR-ABL1 protein and observed its condensation behavior in solution, finding that the protein spontaneously demixes from the aqueous phase to form spherical droplets that fuse with one another and exchange internal contents, hallmarks of a liquid state. In cells, they visualized BCR-ABL1 condensates and correlated their abundance with the speed and completeness of kinase inhibition after tyrosine kinase inhibitor treatment. Crucially, the team collected bone marrow and blood samples from patients with BCR-ABL1-positive leukemia through collaborations with clinicians at Zhejiang Cancer Hospital and the First Hospital of China Medical University, allowing them to test whether condensate behavior in patient-derived cells tracked with treatment response.

The clinical implications of this reframing are substantial. Resistance to tyrosine kinase inhibitors has traditionally been attributed to kinase domain mutations, most famously the T315I substitution that abolishes imatinib binding, or to the persistence of leukemic stem cells that are intrinsically insensitive to the drugs. Studies such as those by Braun and colleagues and by Schneider and colleagues in Nature Cancer have catalogued the biology of these persistent cells, which survive initial therapy and fuel relapse. The phase separation model adds an entirely orthogonal mechanism: a cell can carry a completely drug-sensitive kinase and still mount a delayed response simply because its target protein is packaged inside droplets that physically exclude or retard drug penetration. This innate, non-genetic sluggishness could explain why a measurable fraction of cells in every treated patient survives the earliest hours and days of therapy without carrying any resistance mutation at all.

The finding also resonates with earlier structural and biochemical work on the ABL1 kinase. Structures of ABL1 bound to imatinib, dasatinib and nilotinib published by Tokarski and colleagues revealed exactly how these compounds lock the kinase in its inactive conformation, and kinetic studies showed rapid association rates in purified systems. The paradox between fast in vitro inhibition and slow cellular response now finds a candidate resolution: the purified enzyme in a test tube has no condensate, no barrier and no sluggishness, while the same enzyme inside a leukemic cell is wrapped in a liquid compartment that throttles drug access. Zhao and colleagues’ early structural characterization of the BCR-ABL1 complex, and Smith and colleagues’ dissection of its signaling architecture, provided the molecular map; phase separation now supplies the cellular geography that shapes how drugs navigate that map.

From a therapeutic standpoint, the study suggests that modulating condensate properties could become a strategy to sensitize leukemic cells to existing drugs. If the physical barrier created by BCR-ABL1 condensates is a principal cause of sluggish drug response, then agents that dissolve or destabilize the droplets, or that alter the material properties of the condensate so that small molecules diffuse through it freely, could accelerate and deepen the effect of tyrosine kinase inhibitors. Conversely, the work raises a caution for drug development: potency measured against purified kinase may systematically overestimate how quickly a compound will work in a cell whose target is phase-separated. Screening platforms that incorporate condensate-relevant conditions could help identify compounds that retain efficacy against droplet-sequestered targets, particularly for B-cell acute lymphoblastic leukemia, where early response kinetics strongly influence long-term outcome, as population studies by Qin and colleagues and reports by Ravandi and Molica have documented.

The broader significance extends beyond a single kinase or a single disease. Cancer biologists have increasingly recognized that many oncogenic proteins contain the disordered, multivalent regions that drive phase separation, and that signaling complexes such as those assembled by fusion oncoproteins, including the EML4-ALK and NUP98 fusions studied by Dixon and colleagues in engineered systems, may exploit condensation to amplify and sustain their signals. The BCR-ABL1 study demonstrates that this same organizational principle can also serve as a defensive architecture against therapy. Pendergast and colleagues’ classic 1991 work showed that BCR sequences activate ABL1 tyrosine kinase; three decades later, the new findings suggest that those same BCR-derived regions may coil the fusion protein into droplets that protect the activated kinase from the drugs designed to silence it.

For patients with chronic myeloid leukemia, tyrosine kinase inhibitors have converted a uniformly fatal disease into a manageable chronic condition, and a minority of patients now attempt treatment-free remission under close monitoring. Yet discontinuation fails in a substantial fraction, and persistent cells endure for years. By exposing the physical mechanism behind innate sluggishness, this research opens a new front in the effort to eliminate residual disease: rather than only designing better inhibitors, oncologists may one day prescribe drugs that strip away the droplet shield itself. The image of a cancer protein hiding inside a liquid droplet is a vivid one, and it captures a larger truth about modern biology. Cancer is not only a disease of genes and pathways but of physical organization, and conquering it may require manipulating not just what proteins do, but where and how they gather inside the cell.

Subject of Research: Phase-separated BCR-ABL1 condensates that delay the response of leukemic cells to tyrosine kinase inhibitor therapy

Article Title: Phase separation drives the innate sluggishness of BCR-ABL1 in response to targeted therapy

Article References: Li, G., Wu, J., He, Z., Zhao, J., Chen, H., Zhou, J., Zhang, Q., Wang, Z., Li, Q., & Jiang, P. (2026). Phase separation drives the innate sluggishness of BCR-ABL1 in response to targeted therapy. Cell Research. https://doi.org/10.1038/s41422-026-01286-w

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01286-w

Keywords: BCR-ABL1, phase separation, chronic myeloid leukemia, tyrosine kinase inhibitors, condensates, imatinib, targeted therapy, leukemia, drug resistance, liquid-liquid phase separation, oncology, cell biology

Chronic myeloid leukemia is characterized by the presence of the BCR/ABL fusion gene, resulting from a chromosomal translocation known as the Philadelphia chromosome. This fusion gene encodes a constitutively active tyrosine kinase, which drives uncontrolled proliferation of myeloid cells. While tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of CML, the emergence of the T315I mutation in the BCR/ABL gene often confers resistance to first- and second-generation TKIs. This creates a significant hurdle, necessitating the pursuit of alternative molecular targets and therapeutic strategies.

The recent study conducted by Wang et al. delved deeply into the metabolic adaptations that BCR/ABL-T315I mutant cells undergo in response to metabolic stress. By integrating advanced biochemical assays with state-of-the-art cellular imaging techniques, the researchers demonstrated that GPX1, an antioxidant enzyme responsible for detoxifying reactive oxygen species (ROS), is upregulated in these mutant cells. This upregulation enables the leukemic cells to mitigate the oxidative damage induced by metabolic stress, thereby preserving their survival and proliferative capabilities.

GPX1 functions as a selenium-dependent enzyme that reduces hydrogen peroxide to water, utilizing glutathione as a substrate. In cancer cells, metabolism is often perturbed, leading to an accumulation of ROS, which can inflict oxidative damage on DNA, proteins, and lipids. Normally, excessive ROS levels trigger apoptosis or senescence. However, the ability of BCR/ABL-T315I cells to enhance GPX1 activity means they effectively neutralize lethal ROS concentrations, circumventing metabolically-induced cell death pathways.

The significance of this finding lies in the dual implication for therapeutics. Targeting GPX1, or the antioxidant machinery more broadly, could resensitize resistant CML cells to metabolic stress, restoring the efficacy of TKIs or other metabolic inhibitors. Moreover, as metabolic reprogramming is a hallmark of cancer, understanding the intricacies of redox homeostasis in these malignant cells offers a fresh vantage point for the design of next-generation therapies.

Wang and colleagues employed CRISPR-Cas9 gene editing to knock down GPX1 expression in BCR/ABL-T315I mutant cells. The results were compelling: cells deficient in GPX1 displayed marked sensitivity to metabolic stressors and experienced heightened apoptotic indices. This direct causal link underscores GPX1’s pivotal role in resilience mechanisms and affirms its potential as a therapeutic vulnerability.

Further, the team explored the metabolic fluxes using sophisticated metabolomic profiling, revealing that GPX1 expression correlates with enhanced mitochondrial function and reduced oxidative phosphorylation inefficiencies. This suggests that GPX1 not only acts as a defensive antioxidant shield but also contributes to optimizing energy production, facilitating a metabolic environment conducive to leukemia progression despite genotoxic and metabolic insults.

Intriguingly, these findings align with emerging paradigms in oncology that highlight the relationship between redox regulation and cancer stemness. It is hypothesized that GPX1’s antioxidative role may aid in sustaining leukemic stem cells, notorious for their dormancy and therapy resistance, within the undermetabolically hostile bone marrow niche. Future research may explore GPX1’s role in stem cell biology, potentially refining targeting strategies further.

The study’s methodological rigor also deserves recognition. Utilizing patient-derived xenograft models, Wang et al. validated the in vitro findings by confirming that GPX1 inhibition impaired tumor growth in vivo. This translational approach not only bolsters the biological relevance of GPX1 in CML progression but also provides a viable framework for preclinical testing of GPX1 inhibitors.

From a clinical perspective, these revelations equip oncologists with a novel biomarker for monitoring metabolic adaptations in T315I-mutant CML patients. Measuring GPX1 levels may inform prognosis and therapeutic responsiveness, refining personalized treatment algorithms. Furthermore, the prospect of combining GPX1 inhibitors with existing TKIs could revolutionize treatment paradigms by preempting or overcoming drug resistance.

The implications of this research reverberate beyond CML. Many cancers leverage antioxidant systems to navigate oxidative stress imposed by hypoxia, nutrient deprivation, or chemotherapy. GPX1, therefore, represents a broader target of interest for cancer therapeutics, exemplifying the intersection of metabolism, redox biology, and oncogenic signaling pathways.

As the field progresses, there is an imperative to develop selective and potent GPX1 inhibitors. Current antioxidant-targeting agents lack specificity or impose systemic toxicity, challenging their clinical translation. The identification of molecular pockets and structural determinants unique to GPX1 isoforms in leukemic cells could harness structure-guided drug design, enabling the generation of bespoke agents with minimal off-target effects.

Complementing biochemical approaches, high-throughput screening methodologies and artificial intelligence-driven modeling could accelerate the discovery of allosteric modulators that fine-tune GPX1 activity. Such advancements may also illuminate compensatory antioxidant pathways, facilitating combination therapies that target multiple redox homeostasis nodes simultaneously for maximal efficacy.

Collectively, this work represents a pivotal advance in deciphering the metabolic underpinnings of therapeutic resistance in CML, opening avenues for innovative therapeutic interventions. By illuminating GPX1’s role in mediating survival under metabolic stress in BCR/ABL-T315I mutant cells, Wang et al. have expanded the frontier of targeted cancer therapy.

This research underscores the critical interplay between oncogenes, metabolism, and the cellular antioxidant network, offering hope that the entrenched clinical challenge posed by T315I-driven resistance might soon be surmounted. As the arsenal against CML evolves, integrating metabolic-targeting strategies promises a future where resilient leukemic clones are effectively eradicated, transforming patient outcomes.

In summary, the identification of GPX1 as a metabolic stress resistance factor in T315I-mutated CML cells redefines our understanding of leukemia biology and therapeutic resistance. It emphasizes that tackling metabolic adaptations is as crucial as targeting oncogenic signaling. Subsequent research efforts focusing on this enzyme could herald a new era in combating resistant leukemias and potentially other malignancies reliant on antioxidant defenses.

Subject of Research: Chronic myeloid leukemia, BCR/ABL-T315I mutation, metabolic stress resistance, antioxidant enzyme GPX1

Article Title: GPX1 confers resistance to metabolic stress in BCR/ABL-T315I mutant chronic myeloid leukemia cells

Article References:
Wang, JD., Wang, JX., Lin, ZL. et al. GPX1 confers resistance to metabolic stress in BCR/ABL-T315I mutant chronic myeloid leukemia cells. Cell Death Discov. 11, 229 (2025). https://doi.org/10.1038/s41420-025-02502-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02502-z